Ivonescimab's FDA Approval Bid Falls Through... New Variable in Next-Generation Cancer Drug Race
Summit Therapeutics' Ivonescimab
U.S. FDA approval denied
Failed to demonstrate a survival benefit
Race to develop next-generation cancer immunotherapies draws attention
The first U.S. approval of ivonescimab, a next-generation immunotherapy developed in China, has been denied. Although the drug demonstrated an ability to slow cancer progression, it failed to provide evidence that it significantly extended patients' survival. The setback to the U.S. market entry of the drug, which had drawn attention as a potential rival to blockbuster cancer drug Keytruda, has introduced a new variable into the global race to develop next-generation cancer immunotherapies.
According to the global biotech industry on November 16, Summit Therapeutics said on November 15 (local time) that it had received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its application for approval of ivonescimab. The FDA determined that the submitted data were insufficient to approve the drug. The application covers ivonescimab in combination with chemotherapy for patients with locally advanced or metastatic nonsquamous non-small cell lung cancer whose disease has progressed after treatment with a third-generation epidermal growth factor receptor (EGFR)-targeted therapy.
Ivonescimab is a bispecific antibody developed by China's Akeso that targets the immune checkpoint protein PD-1 and vascular endothelial growth factor (VEGF). It simultaneously blocks PD-1 signaling, which prevents immune cells from attacking, and VEGF, which promotes the formation of blood vessels in tumors. In 2022, Summit Therapeutics secured development and commercialization rights in major markets, including the United States and Europe, in a deal worth up to $5 billion (approximately 6.69 trillion won). In China, the drug was first approved in 2024, and its use was expanded to first-line lung cancer treatment in April 2025. The drug had also attracted expectations from the global pharmaceutical industry: last month, AstraZeneca invested $2 billion (approximately 2.673 trillion won) in Summit Therapeutics and began co-developing a treatment combining ivonescimab with an antibody-drug conjugate (ADC).
In the global Phase 3 HARMONi trial, which supported the application, median progression-free survival (PFS) was 6.8 months in the ivonescimab combination group, longer than the 4.4 months in the control group, which received chemotherapy alone. The combination also reduced the risk of cancer progression or death by 48%. Median overall survival (OS) was 16.8 months, 2.8 months longer than the 14.0 months in the control group, but the difference was not statistically significant (p=0.057). The FDA concluded that, without statistically significant evidence of improved overall survival, improvement in progression-free survival alone was insufficient to show that the treatment's benefits outweighed its risks.
With ivonescimab's U.S. launch delayed, attention is also turning to competitors seeking to catch up. They, too, are developing bispecific antibodies that simultaneously block the immune checkpoint protein PD-1 or PD-L1 and VEGF to overcome the limitations of existing immunotherapies. Germany's BioNTech and U.S.-based Bristol Myers Squibb (BMS) are developing pumitamig (BNT327) in global Phase 3 trials for several cancers, including lung cancer. Pfizer is also conducting a global Phase 3 trial of SSGJ-707, which it licensed from China's 3SBio. Merck (MSD), the U.S. developer of Keytruda, is likewise conducting a global Phase 2 trial of MK-2010, which it licensed from China's LaNova.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Summit Therapeutics is also continuing global clinical development of ivonescimab in other patient groups. In the China-based Phase 3 HARMONi-2 trial, whose results were released in September 2026, ivonescimab showed a greater survival benefit than Keytruda. Among 398 Chinese patients with PD-L1-positive non-small cell lung cancer who had not received prior treatment, median overall survival was 30.8 months in the ivonescimab group, 8.2 months longer than the 22.6 months in the Keytruda group. Summit is currently conducting global Phase 3 trials HARMONi-3 and HARMONi-7 in patients receiving first-line treatment for lung cancer.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.